What is the recommended dosage and administration of macrogol (polyethylene glycol) for treating functional constipation in children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Macrogol (Polyethylene Glycol) for Pediatric Constipation

For children with functional constipation, start polyethylene glycol (PEG) 3350 at 0.7-0.8 g/kg/day for maintenance therapy, with doses ranging from 0.3-1.5 g/kg/day based on response, and use 1-1.5 g/kg/day for disimpaction over 1-6 days until clear liquid stool is achieved.

Maintenance Therapy Dosing

The optimal maintenance dose for pediatric functional constipation is 0.7-0.8 g/kg/day 1, 2. This dosing achieves:

  • Increased stool frequency from baseline 2.3 to 16.9 stools per week
  • Improved stool consistency
  • Reduced soiling episodes by 87% in affected children
  • High palatability and patient satisfaction 2

Dose Adjustment Strategy

Start with 0.7 g/kg/day and adjust every 3 days based on response 2:

  • Target: 2 soft stools per day (Bristol scale 3-4)
  • Increase dose if <3 bowel movements per week
  • Decrease dose if ≥3 bowel movements per day or diarrhea develops
  • Effective range: 0.3-1.5 g/kg/day 1, 3

A lower starting dose of 0.3 g/kg/day is equally effective but requires more frequent dose adjustments (2-fold higher adjustment rate) and results in lower parental satisfaction 1. The higher initial dose of 0.7 g/kg/day provides faster symptom control with similar safety.

Disimpaction Dosing

For fecal impaction, use 1.5 g/kg/day for 3-6 days or until passage of clear liquid stool 4:

  • Continue until disimpaction is confirmed (clear liquid stool passage)
  • Success rate: 84-86% regardless of PEG formulation
  • Most children achieve disimpaction within 6 days

Recent data shows clinicians often use higher doses (4.6-5.3 g/kg/day) for 1-2 day cleanouts 5, which is nearly 3-fold higher than recommended. While these aggressive regimens may work, the standard 1.5 g/kg/day approach over several days is safer and equally effective.

Age-Specific Considerations

Children Under 24 Months

Evidence is limited but supports safety 6:

  • Dosing range: 0.45-1.1 g/kg/day for PEG 3350
  • Adverse effects (diarrhea, abdominal pain) are transient
  • No serious adverse events reported
  • Lack of established optimal dosing requires careful titration

Children Over 24 Months

Standard dosing applies with excellent long-term safety 7:

  • Mean treatment duration: 18.6 months without dose adjustment for weight gain
  • No serious adverse events with prolonged use
  • Sustained clinical improvement in bowel movements and symptoms

Formulation Selection

PEG 3350 (with or without electrolytes) and PEG 4000 are equally effective 4:

  • PEG 4000: Better palatability (statistically significant) but similar compliance
  • PEG 3350 + electrolytes: Theoretical advantage of lower electrolyte imbalance risk
  • Both formulations: 84-86% disimpaction success, similar adverse event profiles

Flavored formulations improve palatability and correlate with better treatment compliance 8. The choice between formulations should prioritize local availability and patient preference.

Duration of Treatment

Continue maintenance therapy for at least 6 months 7:

  • Long-term use (≥6 months) normalizes bowel movements without safety concerns
  • Early discontinuation commonly results in relapse 3
  • No need for dose adjustment due to weight gain during prolonged therapy
  • Parents/caregivers report sustained satisfaction with extended treatment

Common Pitfalls to Avoid

  1. Starting too low: Beginning at 0.3 g/kg/day requires frequent adjustments and delays symptom control
  2. Premature discontinuation: Stopping before 6 months increases relapse risk
  3. Inadequate disimpaction: Must continue until clear liquid stool, not just symptom improvement
  4. Ignoring palatability: Poor taste leads to non-compliance; consider flavored formulations
  5. Excessive dosing for cleanouts: Using >2 g/kg/day for home disimpaction lacks evidence and increases adverse effects 5

Expected Adverse Effects

Mild and transient side effects include 2, 4:

  • Abdominal discomfort (most common)
  • Vomiting
  • Bloating (least likely to improve)
  • Diarrhea (dose-dependent)

No serious adverse events have been reported in pediatric populations across multiple studies, including long-term use 6, 7.

Monitoring Response

Assess treatment success weekly:

  • Success criteria: ≥3 bowel movements per week with no fecal soiling
  • Track stool consistency using Bristol Stool Scale (target: type 3-4)
  • Document soiling episodes
  • Adjust dose every 3 days if targets not met

Related Questions

What is the recommended pediatric dosage of polyethylene glycol (PEG) syrup per kilogram of body weight for constipation maintenance and short‑term disimpaction?
What is the recommended dosing and administration of macrogol (polyethylene glycol) for treating constipation in children, including infants under 2 years?
What is the appropriate dose of MiraLAX (polyethylene glycol 3350) for a 19‑month‑old child weighing approximately 24 lb (≈11 kg) with constipation, and how should it be administered?
What is the recommended management for functional constipation in a toddler, including fluid intake, dietary fiber, activity, toileting routine, and polyethylene glycol (PEG 3350) dosing?
What is the appropriate prescription for polyethylene glycol 3350 for a 14‑year‑old adolescent with a one‑month history of constipation and intermittent abdominal discomfort?
What is the recommended dosing and administration of macrogol (polyethylene glycol) for treating constipation in children, including infants under 2 years?
Is cefepime safe for use during pregnancy, and what dosing adjustments are recommended for a pregnant adult with normal renal function?
Which monitoring tests should be performed for a 35‑year‑old male five years after renal transplantation who is taking mycophenolate mofetil (Renodapt S) 720 mg in the morning and 360 mg in the evening, prednisone (Wysolone) 5 mg each morning, tacrolimus 1 mg in the morning and 0.75 mg in the evening, amlodipine 5 mg daily, telmisartan 20 mg daily, and metoprolol extended‑release 25 mg daily?
What is the appropriate treatment for an acute knee ligament injury?
How should we manage an elderly hypertensive, non‑diabetic woman who presents with persistent diarrhea (3–4 loose stools per day) that has not improved with her usual treatment?
What adjuvant chemoradiotherapy regimen should be given to an adult patient after curative‑intent esophageal cancer surgery, especially if high‑risk pathological features (positive margins, nodal involvement, or T3‑T4 disease) are present?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.